1. An isolated oligopeptide selected from the group consisting of (i) and (ii) below:(I) isolated oligopeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 2 and 4(Ii) isolated oligopeptide which consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 2 and 4, in which one, two or more amino acids are inserted, substituted, added or removed,wherein said oligopeptide is capable of inducing T-lymphocytes (CTL).2. The oligopeptide (ii) of claim 1, wherein said oligopeptide has one or both of the following characteristics:(A) the second amino acid from the N-end selected from methionine and leucine and(B) C-terminal amino acid selected from valine and leucine.3. An isolated oligopeptide of claim 1 or 2, wherein said oligopeptide is a nonapeptide or decapeptide.4. An isolated polynucleotide encoding the oligopeptide according to any one of claims 1-3.5. The agent for inducing CTL, wherein the agent comprises one or more oligopeptides as claimed in any one of claims 1-3, or one or more polynucleotides of claim 4.6. A pharmaceutical agent for the treatment and / or prevention of cancer and / or prevention of postoperative recurrence it, wherein the agent comprises one or more oligopeptides as claimed in any one of claims 1-3, or one or more polynucleotides of claim 4.7. A pharmaceutical agent according to claim 6, which is mixed for administration to a subject whose HLA-antigen is HLA-A2.8. The pharmaceutical agent of claim 6 or 7, which is mixed for the treatment of cancer.9. A method of inducing antigen-presenting cells (APCs) with the ability to induce a CTL, wherein the method comprises one of the following steps:(A) bringing into contact with the APC oligopeptide according to any of claims 1-3 in vitro, ex vivo or in vivo or(B) insertion of a polynucleotide encoding the oligopeptide according to any of claims 1-3, APC.10. A method for inducing CTL by any method comprising at least one of the follo
